ALBANY MOLECULAR RESEARCH INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statement of cash flows

In millions of USD, except per-share amounts

	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012
Operating Activities
Net loss
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization
Deferred financing amortization
Accretion of discount on long-term debt
Provision for doubtful accounts
Forgiven principal on notes receivable
Deferred income tax
Goodwill impairment
Property and equipment impairment
Impairment charges
Loss on disposal of property, plant and equipment
Loss on disposal of property and equipment
Cumulative translation loss related to foreign subsidiary dissolution
Share-based compensation expense
Gain on settlement of post-retirement liability
Excess tax benefit of stock option exercises
Other
Changes in operating assets and liabilities that provide (use) cash, net of impact of business combinations:
Accounts receivable
Royalty income receivable
Inventory
Prepaid expenses and other assets
Accounts payable, accrued compensation and accrued expenses
Arbitration reserve
Income taxes receivable/payable
Deferred revenue and licensing fees
Pension and postretirement benefits
Other long-term liabilities

Net cash provided by operating activities
Investing Activities
Purchases of marketable securities
Proceeds from sales and maturities of marketable securities
Purchase of businesses, net of cash acquired
Purchases of property and equipment
Payments for patent applications and other costs
Proceeds from disposal of property and equipment
Net cash used in investing activities

Financing Activities
Issuance of short-term borrowings
Principal payments on short-term borrowings
Issuance of long-term debt
Proceeds from sale of warrants
Payment for bond hedge options
Principal payments on long-term debt
Deferred financing costs
Purchases of treasury stock
Changes in restricted cash
Excess of tax benefit of stock option exercises
Proceeds from exercise of options and Employee Stock Purchase Plan
Net cash provided by financing activities
Effect of exchange rate changes on cash flows
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosure of non-cash activities:
Unrealized loss on securities available-for-sale, net of tax
Actuarial gain (loss) on pension and other postretirement liability, net of tax
Issuance of common stock for business acquisition
Issuance of restricted stock
Equipment purchase financed with a capital lease
Non-cash forgiveness of arbitration reserve
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest
Income taxes

Comments